Introduction {#section1-1533033818785980}
============

Hepatocellular carcinoma (HCC) is a common malignant tumor, the fifth most common cancer worldwide for men and the ninth most frequent cancer for women.^[@bibr1-1533033818785980]^ Hepatocellular carcinoma is associated with high mortality and poor prognosis, causing 500 000 deaths annually.^[@bibr2-1533033818785980][@bibr3-1533033818785980]--[@bibr4-1533033818785980]^ Hepatocellular carcinoma is more common in Asia and Africa, but its incidence has increased over the last several decades in Western countries.^[@bibr5-1533033818785980]^

Although liver resection and transplantation are the most effective means for treating HCC, these procedures are suitable only for \<20% of patients due to a high risk of intraoperative blood loss and perioperative transfusions, which directly influence postoperative morbidity and mortality.^[@bibr6-1533033818785980][@bibr7-1533033818785980][@bibr8-1533033818785980]--[@bibr9-1533033818785980]^ To improve the safety of surgery, more secure techniques have been developed.^[@bibr10-1533033818785980][@bibr11-1533033818785980][@bibr12-1533033818785980][@bibr13-1533033818785980][@bibr14-1533033818785980]--[@bibr15-1533033818785980]^ Local tumor thermal ablation allows fast heating, partial inactivation tissue, less trauma, and fewer complications.^[@bibr16-1533033818785980],[@bibr17-1533033818785980]^ Moreover, thermal-assisted liver resection is also virtually bloodless.^[@bibr18-1533033818785980]^

Microwave ablation (MWA), a new thermal ablation approach which was introduced in the 1990s, has emerged as a promising, minimally invasive treatment option. Microwave (MW) can deliver relatively high temperature into the tumor over a short time and cover a large ablation zone, which can improve ablation efficiency with less cardiovascular events.^[@bibr19-1533033818785980]^ Recently, it has been thought that MWA may be a valuable alternative method for treating hepatic disease.^[@bibr20-1533033818785980]^ One randomized study showed that MWA was equally effective as surgery for treating hepatic metastases.^[@bibr21-1533033818785980]^

Microwave ablation is gaining acceptance for local therapy due to its demonstrable clinical benefits. Thus, we evaluated the effect of an approach to combining MWA and liver resection for HCC. The primary measurable outcomes were intraoperative blood loss and postoperative recovery index. We also analyzed the length of hospital stay, postoperative morbidity, and survival time.

Patients and Methods {#section2-1533033818785980}
====================

Patient Enrollment {#section3-1533033818785980}
------------------

We enrolled 79 patients who underwent liver resection for HCC at the Liver Transplantation Center of the First Affiliated Hospital of Nanjing Medical University from January 1, 2014, to March 30, 2014. Patients were randomized to group A, liver resection without MWA (n = 40), or group B, MWA-assisted liver resection (n = 39). The flowchart of patient enrollment of this study is shown in [Figure 1](#fig1-1533033818785980){ref-type="fig"}.

![Flowchart of patient enrollment.](10.1177_1533033818785980-fig1){#fig1-1533033818785980}

Patient inclusion criteria are as follows: (1) surgical specimens with confirmed HCC; (2) total number of tumor lesions ≤3; (3) largest single tumor diameter ≤10 cm; (4) for patients with multiple tumors (2 or 3), no more than one lesion \>5 cm; (5) Child-Pugh score A or B; (6) no distant metastasis; and (7) no MWA treatment contraindications.

Patient exclusion criteria are as follows: (1) incomplete clinic pathological data; (2) patients who received anticancer treatment before surgery, such as hepatic resection, sorafenib, radiofrequency ablation, or transcatheter arterial chemoembolization; (3) patients with portal vein, hepatic vein or inferior vena cava invasion, extrahepatic metastases, or malignancies of other tissue of origin; (4) patients with signs of decompensated cirrhosis such as clinical hepatic encephalopathy and refractory ascites; and (5) lost to follow-up.

Ethics committee of the First Affiliated Hospital of Nanjing Medical University (approval number: 2013-SR-092) approved the study. Informed consents from patients to allow the review and analyses of their medical records were obtained.

Surgical Procedure {#section4-1533033818785980}
------------------

All surgical procedures were performed by skilled surgical teams. For group A, local hepatectomy or regular hepatectomy of left or right lobe was performed according to tumor size and location. Group B was treated with MWA before resection. Microwave ablation was performed at the scheduled resection plane, and the surgical electrode needle was punctured into the side of the tumor at the plane and then gradually pushed forward, overlapping many times, to cover the entire resection plane. Then, conventional hepatectomy was performed. A 100 ECO MWA device (Nanjing YiGao Engineering Co Ltd, Jiangsu, China) was used at a frequency of 2450 MHz and a maximum output power of 100 W. There was a 16-G insulation antisticking puncture guide needle for tumor puncture into the MW electrode and insulation of the implanted MW antenna ([Figure 2](#fig2-1533033818785980){ref-type="fig"}).

![A, Perioperative contrast-enhancement CT showing a tumor of approximately 2 × 2 cm (a 65-year-old female patient with HCC). B, Follow-up CT 6 months after liver resection without MWA. C, Perioperative contrast-enhancement CT showing a tumor of approximately 3.6 × 3 cm (a 50-year-old male patient with HCC). D, Follow-up CT 6 months after MWA-assisted liver resection. CT indicates computed tomography; HCC, hepatocellular carcinoma; MWA, microwave ablation.](10.1177_1533033818785980-fig2){#fig2-1533033818785980}

Data Analysis {#section5-1533033818785980}
-------------

Demographic, clinical, imaging, biological, and surgical data were analyzed. Lab tests (eg, alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], albumin, total bilirubin \[TB\], prothrombin time \[PT\], and alpha fetoprotein \[AFP\]) were performed preoperatively and 7 days after surgery. Patients were assessed using the Child-Pugh classification and Model for End-Stage Liver Disease scores. Tumor volume was estimated by computed tomography volumetric computing. Surgical time and blood loss were recorded and analyzed. Blood transfusion was performed when hemoglobin decreased to below 8 g/dL or blood loss during surgery was above 400 mL. Resected specimens were analyzed histopathologically to confirm their status. Postoperative median follow-up was 18 months (range: 7-40 months). Tumor recurrence, metastasis, and mortality were also recorded. Deaths occurring within postoperative 30 days were referred to as postoperative mortality.

Statistical Analysis {#section6-1533033818785980}
--------------------

All data were encoded and analyzed using SPSS 19.0 statistical software. Data from both groups are presented as numbers and percentages. Descriptive and bivariate statistics (Student *t* test, Pearson χ^2^, and Cox regression analyses) were used. Data are means (standard deviation). Survival time was computed using the Kaplan-Meier function. For analyses, *P* \< .05 indicated statistical significance.

Results {#section7-1533033818785980}
=======

Clinical demographics of all patients are summarized in [Table 1](#table1-1533033818785980){ref-type="table"}. Preoperative and postoperative biological data including AFP level and liver function tests (serum albumin, ALT, AST, TB, and PT) are summarized in [Table 2](#table2-1533033818785980){ref-type="table"}. There was no significant difference between these 2 groups. Operative risks and postoperative complications are summarized and assessed in [Table 3](#table3-1533033818785980){ref-type="table"}. Cases of blood loss above 200 mL were significantly less in group B than that in group A (*P* \< .001). There was no significant difference in surgical time and blood transfusion between these 2 groups.

###### 

Demographic and Clinical Data.

![](10.1177_1533033818785980-table1)

  Characteristics     Group A (n = 40)        Group B (n = 39)       *P* Value
  ------------------- ----------------------- ---------------------- -----------
  Age (\>55 years)    28 (70.0%)              21 (53.8%)             .138
  BMI (\>24)          15 (37.5%)              12 (30.8%)             .528
  Sex (male/female)   29 (72.5%)/11 (27.5%)   31 (79.5%)/8 (20.5%)   .467
  Smoke               9 (22.5%)               10 (25.6%)             .744
  Alcohol             6 (15.0%)               6 (15.4%)              .962
  Diabetes            4 (10.0%)               5 (12.8%)              .693
  Hypertension        9 (22.5%)               8 (20.5%)              .830
  HBV                 24 (60.0%)              24 (61.5%)             .889
  Liver cirrhosis     26 (65.0%)              24 (61.5%)             .750
  Child-Pugh class                                                   
   Child A            22 (90.9%)              22 (91.7%)             .900
   Child B            4 (10.0%)               2 (8.3%)               .409
  Symptomatic HCC     36 (90.0%)              33 (84.6%)             .471

Abbreviations: BMI, body mass index; HBV, Hepatitis B Virus; HCC, hepatocellular carcinoma.

###### 

Preoperative and 7 Days Postoperative Biological Data.

![](10.1177_1533033818785980-table2)

  Characteristics                      Group A (n = 40)   Group B (n = 39)   *P* Value
  ------------------------------------ ------------------ ------------------ -----------
  AFP (\>400 μg/L)                     34 (85.0%)         30 (76.9%)         .359
  Albumin (\>35 mg/dL) preoperative    20 (50.0%)         20 (51.3%)         .909
  Albumin (\>35 mg/dL) postoperative   25 (62.5%)         25 (64.1%)         .883
  ALT (\>40 U/L) preoperative          40 (100%)          39 (100%)          1.000
  ALT (\>40 U/L) postoperative         28 (70.0%)         26 (66.7%)         .750
  AST (\>40 U/L) preoperative          40 (100%)          39 (100%)          1.000
  AST (\>40 U/L) postoperative         10 (25.0%)         9 (23.1%)          .841
  TBIL (\>25 μmol/L) preoperative      11 (27.5%)         7 (17.9%)          .310
  TBIL (\>25 μmol/L) postoperative     5 (12.5%)          6 (15.4%)          .711
  PT (\>14 seconds) preoperative       2 (5.0%)           1 (2.6%)           .567
  PT (\>14 seconds) postoperative      11 (27.5%)         8 (20.5%)          .467

Abbreviations: AFP, alpha fetoprotein; AST, aspartate amino transferase; ALT, alanine amino transferase; PT, prothrombin time; TBIL, total bilirubin.

###### 

Operative and Postoperative Data.

![](10.1177_1533033818785980-table3)

  Characteristics                  Group A (n = 40)   Group B (n = 39)   *P* Value
  -------------------------------- ------------------ ------------------ -----------
  Operation time (\>180 minutes)   19 (47.5%)         19 (48.7%)         .914
  Tumor diameter                                                         
   \<3 cm                          3 (7.5%)           10 (25.6%)         0.026
   3-5 cm                          20 (50.0%)         18 (46.2%)         .732
   \>5 cm                          17 (42.5%)         11 (28.2%)         .183
  Multiple tumors                  4 (10.0%)          5 (12.8%)          .693
  Blood loss (\>200 mL)            28 (70.0%)         10 (25.6%)         .000
  Blood transfusion                11 (27.5%)         10 (25.6%)         .852
  Drainage day 1 (\>100 mL)        19 (47.5%)         7 (17.9%)          .005
  Drainage day 3 (\>100 mL)        18 (45.0%)         8 (20.5%)          .019
  Drainage day 7 (\>100 mL)        9 (22.5%)          5 (12.8%)          .257
  Pyrexia                          12 (30.0%)         8 (20.5%)          .331
  Complications                    4 (10.0%)          3 (7.7%)           .718
  Postoperative hospital stay                                            
   \>10 days                       33 (82.5%)         13 (33.3%)         .000
  Cost (\>\$7000)                  24 (60.0%)         28 (71.8%)         .268
  Late postoperative morbidity     4 (10.0%)          2 (5.1%)           .409
  Recurrence                       11 (27.5%)         4 (10.2%)          .047
  Metastasis                       9 (22.5%)          3 (7.7%)           .061

All patients in both groups were discharged, and there were no deaths or serious complications during the perioperative period. However, the hospital stay of above 10 days in group A was significantly longer than that in group B (*P* \< .001). Postoperative drainage volume in group B was less than that in group A on the first (*P* = .005) and third (*P* = .019) day after surgery. Both groups had similar postoperative morbidity and late postoperative morbidity (eg, chronic liver failure, ascites, and postoperative incision hernias). Local recurrence of HCC was significantly lower in group B (*P* = .047); however, distant metastases in lungs and bones were found in 9 and 3 patients, respectively, in groups A and B, which was not significant (*P* = .061).

The 1-year and 3-year survival rates were 93.7% and 57.0%, respectively. The 3-year survival rate of group A (47.5%) was lower than that of group B (66.7%; [Figure 3B](#fig3-1533033818785980){ref-type="fig"}), and differences are statistically significant (*P* = .044). There was a difference in follow-up time between the 2 groups.

![A, Overall survival time. B, Survival time in the 2 groups (Kaplan-Meier).](10.1177_1533033818785980-fig3){#fig3-1533033818785980}

Discussion {#section8-1533033818785980}
==========

Surgery is the primary treatment for patients with HCC, and traditional liver resection which brings much trauma affects prognosis and recovery of patients. Partial hepatectomy is the main treatment for patients with HCC, but for those with a high risk of recurrence, auxiliary MWA may be used to reduce recurrence.^[@bibr22-1533033818785980][@bibr23-1533033818785980]--[@bibr24-1533033818785980]^

One randomized study showed that MWA was equally effective as surgery for treating hepatic metastases,^[@bibr21-1533033818785980]^ and research suggests that thermal ablation therapy is useful^[@bibr25-1533033818785980]^; however, the long-term surgical effects of this approach have not been well studied.^[@bibr26-1533033818785980]^ We report that average blood loss was significantly less in MWA-assisted group, and postoperative drainage of the study group was less than that of controls too. Postoperative hospitalization time was significantly shorter in the MWA-assisted group, and after 3 years of follow-up, the survival rate of MWA-assisted group was significantly greater than that of the liver resection group, which suggests that MWA-assisted partial liver resection for HCC is beneficial. Conventional partial hepatectomy requires repeated hepatic portal occlusion, which can control bleeding, but is limited and may lead to hepatic ischemia--reperfusion injury; this can be injurious to patients with liver cirrhosis^[@bibr14-1533033818785980],[@bibr27-1533033818785980]^ and cause liver dysfunction or failure.

Group B was treated with MWA with conventional surgical resection and friction, and heat produced by MWA caused cellular death via coagulation necrosis.^[@bibr12-1533033818785980],[@bibr28-1533033818785980]^ This created local tissue protein coagulation and necrosis and was effective for reducing tumor cells along cancer margins as well as inducing hemostasis, which contributed to bloodless hepatectomy. Better recovery after MWA was also noted due to complete hemostasis, and postoperative drainage was significantly reduced, which reduced the length of hospital stay.

Microwave ablation is a well-known technique in the treatment of hepatic malignant tumors to show low incidence of postoperative complications.^[@bibr29-1533033818785980]^ According to a large-scale multicenter study over 13 years, complications occurred in 2.9% of patients,^[@bibr30-1533033818785980]^ including bile duct injury, bleeding artery embolization, hepatic abscess and empyema, colonic perforation, skin burns, and tumor transplantation. Fever was one of the common side effects, and more than 83.4% of patients had fever for 24 to 48 hours after surgery.^[@bibr31-1533033818785980]^

Thermal ablation therapy assisted liver resection by which coagulated liver parenchyma "seals" the tumor.^[@bibr32-1533033818785980][@bibr33-1533033818785980]--[@bibr34-1533033818785980]^ Overall survival for liver resection with and without MWA is 40% for both groups after 3 years^[@bibr35-1533033818785980]--[@bibr36-1533033818785980]^ in the literature, and our data are similar. In particular, survival for both groups after 1 year was 90.0% and 97.4%, respectively, and survival for group B after 3 years was higher than that of group A. This may be due to more patients with small HCC in group B. This study is limited by the small number of cases, its observational nature, and the shorter follow-up time.

Conclusions {#section9-1533033818785980}
===========

Microwave ablation--assisted liver resection is a feasible and safe procedure for the treatment of HCC and allows liver resection with lower metastasis and recurrence rate. Blood loss was less when compared to conventional procedures, and the patients recovered faster with shorter hospital stays.
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